UroGen Pharma Ltd.
For the period ended Dec 31, 2025. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 2, 2026
URGN$26.31+6.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share amounts and par value)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $110,745 | $171,987 |
| Marketable securities | 9,711 | 64,698 |
| Restricted cash | 1,350 | 1,076 |
| Accounts receivable, net | 33,082 | 20,302 |
| Inventories | 16,464 | 9,227 |
| Prepaid expenses and other current assets | 14,672 | 8,845 |
| Total current assets | 186,024 | 276,135 |
| Non-current assets: | ||
| Property and equipment, net | 637 | 655 |
| Restricted deposit | 177 | 176 |
| Right-of-use assets | 8,456 | 3,134 |
| Marketable securities | — | 5,022 |
| Other non-current assets | 5,161 | 589 |
| Total Assets | $200,455 | $285,711 |
| Liabilities and Shareholders' Deficit | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $27,717 | $27,431 |
| Employee related accrued expenses | 13,516 | 10,570 |
| Other current liabilities | 5,185 | 7,948 |
| Total current liabilities: | 46,418 | 45,949 |
| Non-current liabilities: | ||
| Prepaid forward obligation | 127,276 | 121,387 |
| Long-term debt | 122,210 | 121,734 |
| Long-term lease liabilities | 6,122 | 1,653 |
| Uncertain tax positions liability | 3,903 | 3,791 |
| Total Liabilities | 305,929 | 294,514 |
| Commitments and Contingencies (Note 20) | ||
| Shareholders' Deficit: | ||
| Ordinary shares, NIS 0.01 par value; 100,000,000 shares authorized at December 31, 2025 and 2024; 48,350,272 and 42,231,746 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 133 | 115 |
| Additional paid-in capital | 854,090 | 797,248 |
| Accumulated deficit | (959,716) | (806,222) |
| Accumulated other comprehensive income | 19 | 56 |
| Total Shareholders' Deficit | (105,474) | (8,803) |
| Total Liabilities and Shareholders' Deficit | $200,455 | $285,711 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.